Schizophrenia Trial, Recruiting NCT07196462 Sponsor: Vanderbilt University Medical Center Condition: Schizophrenia
Back to Schizophrenia

Schizophrenia Trial, Recruiting

NCT07196462
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For people with a psychotic disorder:

  • People aged between 18 and 65 years old
  • People who have been diagnosed with a psychotic disorder, confirmed using a standard diagnostic interview called the SCID
  • People who are currently using cannabis, at a level of at least 2 out of 10 on a rating scale, confirmed by a urine test
  • People who can read, speak, and understand English
  • People who study staff judge to be capable of completing all study procedures
  • People who are receiving stable outpatient psychiatric care, have not been hospitalised for psychiatric reasons in the past 30 days, and have not had any changes to their psychiatric medications in the past 30 days

For healthy volunteers (people without a psychotic disorder):

  • All of the same criteria above apply, except participants in this group must not have a diagnosis of a psychotic disorder, and must not have a close biological family member (parent, sibling, or child) with a psychotic disorder

Who may not be able to join:

  • People diagnosed with an intellectual disability according to DSM-5 criteria
  • People who have had a substance use disorder (other than cannabis or nicotine) within the past three months
  • People whose urine drug test shows the presence of cocaine, benzodiazepines, amphetamine, or methamphetamine, as these substances can increase seizure risk
  • People with a history of a progressive or genetic neurological condition (such as Parkinson's disease, multiple sclerosis, or Alzheimer's disease) or an acquired neurological condition (such as stroke, brain injury, or brain tumour), including any lesions inside the skull
  • People who have had a head injury that caused loss of consciousness lasting more than 15 minutes, or that caused lasting neurological effects
  • People who currently experience poorly controlled headaches, including those taking regular medication to prevent migraines
  • People with a history of unexplained fainting episodes that may have been seizures
  • People with a personal history of seizures or epilepsy, or who have a close biological family member with epilepsy, except where a single seizure occurred for a straightforward reason (such as a childhood febrile seizure), as determined by a specialist neurologist
  • People with ongoing, poorly controlled medical conditions that could become dangerous if a seizure were to occur (such as certain heart or breathing conditions)
  • People who have any metal in their brain or skull (not including standard dental fillings) or elsewhere in their body, unless a responsible doctor has reviewed and cleared this (for example, some MRI-compatible joint replacements may be acceptable)
  • People who have an implanted device such as a pacemaker, medication pump, nerve stimulator, TENS unit, or a shunt in the brain, unless a responsible doctor has reviewed and cleared this
  • People who are pregnant or planning to become pregnant during the study period (a pregnancy test will be required for all female participants of childbearing age)
  • People whose medications are assessed by the responsible covering doctor as not suitable for participation, based on factors such as the type of medication, dose, how recently it was started or changed, and its effects on brain activity
  • People who have had any medication changes or hospitalisations within the past 30 days
  • People who, in the investigators' opinion, may not be suitable for the study or may not be able to tolerate the study visit procedures

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 6154345891

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
15 January 2026
Est. completion
31 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Clinical Efficacy: Determine if rTMS affects cue-induced craving and if craving change correlates with change in functional connectivity (n=100).

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov